HUP0003267A2 - Heteroarilszármazékok, e vegyületeket tartalmazó gyógyászati készítmények és eljárás előállításukra - Google Patents

Heteroarilszármazékok, e vegyületeket tartalmazó gyógyászati készítmények és eljárás előállításukra

Info

Publication number
HUP0003267A2
HUP0003267A2 HU0003267A HUP0003267A HUP0003267A2 HU P0003267 A2 HUP0003267 A2 HU P0003267A2 HU 0003267 A HU0003267 A HU 0003267A HU P0003267 A HUP0003267 A HU P0003267A HU P0003267 A2 HUP0003267 A2 HU P0003267A2
Authority
HU
Hungary
Prior art keywords
group
alkylene
heteroalkylene
oxoalkylene
amino
Prior art date
Application number
HU0003267A
Other languages
English (en)
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Arris Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical Corporation filed Critical Arris Pharmaceutical Corporation
Publication of HUP0003267A2 publication Critical patent/HUP0003267A2/hu
Publication of HUP0003267A3 publication Critical patent/HUP0003267A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgyát triptáz inhibitor hatású, (I) általános képletűvegyületek, amely képletben X5 jelentése cikloalkilén-,heterocikloalkilén-, arilén- vagy heteroariléncsoport; és X4 és X6jelentése külön-külön alkiléncsoport; vagy X4-X5-X6 jelentéseegyüttesen egy alkilén- vagy heteroalkiléncsoport; X1 és X9 jelentésekülön-külön kovalens kötés vagy oxigéntartalmú csoport, X3 és X7jelentése külön-külön oxigéntartalmú csoport; X2 és X8 jelentésekülön-külön alkilén- vagy heteroalkiléncsoport, vagy -X10-X11- vagy -X11-X10- csoportok, amelyekben X10 jelentése alkilén- vagyheteroalkiléncsoport; és X11 jelentése cikloalkilén- vagyheterocikloalkiléncsoport; R1 jelentése R4-X12- vagy R5-X13-csoport,amelyben R4 jelentése amino-, amidino-, guanidino-, 1-imino-etil- vagymetil-amino-csoport; X12 jelentése alkilén-, heteroalkilén-, hetero-oxo-alkilén-, oxo-alkilén-, vagy -X14-X15-X16-csoport; R5 jelentéseegy heterociklusos csoport, vagy annak bármely karbociklusos keton-vagy tioketonszármazéka, X13 jelentése alkilén-, hetero-alkilén-,hetero-oxo-alkilén-, oxo-alkilén-, vagy -X17-X18-X19 csoport; R2jelentése egy R8-X20- vagy R9-X21- csoport, amelyben R8 jelentésebizonyos megkötésekkel amino-, 1-imino-etil- vagy metil-amino-csoport;X20 jelentése alkilén-, hetero-alkilén-, hetero-oxo-alkilén-, oxo-alkilén-, vagy -X22-X23-X24-csoport; R9 jelentése megegyezik az R5fenti jelentésével; és X21 jelentése megegyezik X13 fentijelentésével; azzal a megszorítással, hogy kovalens kötés nincs az R1,X2, X4, X6, X8 és R2 csoport heteroatomjai között, és bármely, az X3,X5, X7 és X9 által tartalmazott heteroatomok között; valamint ennekgyógyszerészetileg elfogadható sói, N-oxidjai, prodrug- és védettszármazékai képezik. Ó
HU0003267A 1996-07-30 1997-07-30 Heteroaryl derivatives, pharmaceutical compositions containing them and process for producing them HUP0003267A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
HUP0003267A2 true HUP0003267A2 (hu) 2001-06-28
HUP0003267A3 HUP0003267A3 (en) 2002-02-28

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003267A HUP0003267A3 (en) 1996-07-30 1997-07-30 Heteroaryl derivatives, pharmaceutical compositions containing them and process for producing them

Country Status (17)

Country Link
EP (1) EP0934293A1 (hu)
JP (1) JP2001509787A (hu)
KR (1) KR20000029679A (hu)
CN (1) CN1073103C (hu)
AU (1) AU733621B2 (hu)
CA (1) CA2262542A1 (hu)
CZ (1) CZ29799A3 (hu)
EE (1) EE9900036A (hu)
FI (1) FI990171A (hu)
HU (1) HUP0003267A3 (hu)
LV (1) LV12291B (hu)
NO (1) NO990433L (hu)
NZ (1) NZ333713A (hu)
PL (1) PL331465A1 (hu)
SI (1) SI9720047A (hu)
SK (1) SK8599A3 (hu)
WO (1) WO1998004537A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
JP2002502845A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
US6489327B1 (en) * 1998-02-06 2002-12-03 Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. Tryptase inhibitors
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
AU777026B2 (en) * 1999-08-10 2004-09-30 Altana Pharma Ag Novel tryptase inhibitors
WO2001019809A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE60011677T2 (de) * 1999-12-20 2005-07-14 Altana Pharma Ag Tryptase-inhibitoren
ATE268322T1 (de) 1999-12-20 2004-06-15 Altana Pharma Ag Inhibitoren der tryptase
US6924305B2 (en) 2001-01-31 2005-08-02 Altana Pharma Ag Diazocine derivatives and their use as tryptase inhibitors
WO2002066420A2 (en) * 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
AU2002254941B2 (en) * 2001-03-15 2007-05-17 Altana Pharma Ag Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR100958552B1 (ko) 2001-06-11 2010-05-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
AU2002314165B2 (en) 2001-06-19 2008-02-21 Altana Pharma Ag Tryptase inhibitors
CN102429882B (zh) 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
JP7373191B2 (ja) * 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスａ ｇｐｃｒ結合性化合物改変体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
CZ289930B6 (cs) * 1993-03-12 2002-04-17 Axys Pharmaceuticals, Inc. Arylové a heteroarylové peptidové deriváty a farmaceutické prostředky je obsahující
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
CN1160398A (zh) * 1994-09-23 1997-09-24 阿瑞斯药物公司 治疗肥大细胞炎性疾病的组合物和方法
PL322409A1 (en) * 1995-03-24 1998-01-19 Arris Pharm Corp Reversible protease inhibitors
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
CA2262542A1 (en) 1998-02-05
CN1226892A (zh) 1999-08-25
SI9720047A (sl) 1999-08-31
LV12291B (en) 2000-04-20
FI990171A0 (fi) 1999-01-29
CN1073103C (zh) 2001-10-17
KR20000029679A (ko) 2000-05-25
PL331465A1 (en) 1999-07-19
AU3967097A (en) 1998-02-20
AU733621B2 (en) 2001-05-17
HUP0003267A3 (en) 2002-02-28
FI990171A (fi) 1999-03-23
NO990433D0 (no) 1999-01-29
EE9900036A (et) 1999-08-16
JP2001509787A (ja) 2001-07-24
EP0934293A1 (en) 1999-08-11
WO1998004537A1 (en) 1998-02-05
NZ333713A (en) 2000-12-22
LV12291A (lv) 1999-06-20
CZ29799A3 (cs) 1999-06-16
SK8599A3 (en) 2000-03-13
NO990433L (no) 1999-03-25

Similar Documents

Publication Publication Date Title
HUP0003267A2 (hu) Heteroarilszármazékok, e vegyületeket tartalmazó gyógyászati készítmények és eljárás előállításukra
HUP0100949A2 (hu) Aril kondenzált azapoliciklusos vegyületek és ezeket tartalmazó gyógyászati készítmények
HUP0301195A2 (hu) Alfa-4 integrin antagonista hatású aza-hidas biciklusos aminosav-származékok és ilyen vegyületeket tartalmazó gyógyszerkészítmények
GR3032395T3 (en) New aminoacid derivates, process for producing the same and pharmaceutical compositions containing these compounds.
ATE104279T1 (de) 4-fluorbenzolderivate, herstellungsverfahren und diese enthaltende pharmazeutische zusammensetzungen.
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
DE69713148D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
DE69713152D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
CA2054850A1 (en) Cyclic imino derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
HUP0003309A2 (hu) Imidazolilcsoportot tartalmazó gyűrűs acetálok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
ATE13740T1 (de) Peptidester, verfahren zur herstellung derselben und diese enthaltende arzneimittel beziehungsweise diagnostica.
HUP9802762A2 (hu) Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
DK0734383T3 (da) Cykliske amidderivater som neurokinin-A-antagonister
ES2156933T3 (es) Derivados triciclicos de benzazepina y benzotiazepina.
HUP9802121A2 (hu) Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
CA2314154A1 (en) Azepine or larger medium ring derivatives and their use as pharmaceuticals
HUP0000321A2 (hu) NOS inhibitor hatású aromás aminszármazékok, eljárás előállításukra, valamint a vegyületeket tartalmazó gyógyszerkészítmények
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
HUP0004331A2 (hu) A fankinon (4,7-fenantrolin-5,6-dion alkalmazása az Alzheimer-kór kezelésére szolgáló gyógyszerkészítmények előállítására és ezt tartalmazó kombinált gyógyszerkészítmény
DK0632026T3 (da) Alfa-aminosyrederivater, en fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
DE69710909D1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
HUP0204217A2 (en) Novel a-500359 derivatives
GEP20032924B (en) Novel Furan Diarylmethylidene Derivatives, Method for Their Preparation and Pharmaceutical Composition
DE59404784D1 (de) Neue carbonsäureester von 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purin, deren herstellung sowie deren verwendung
GEP20032929B (en) 6-O-Methyl-Erythromycin A Class, Novel 8a-and 9a-15-Membered Lactams, Method for Their Production and Pharmaceutical Composition for Treatment of Bacterial Infections